Global Fecal Calprotectin Assays Market Growth 2026-2032

October 2026 | 217 pages | ID: G23E6ED526BDEN
LP Information

Abstracts

The global Fecal Calprotectin Assays market size is predicted to grow from US$ 213 million in 2025 to US$ 385 million in 2032; it is expected to grow at a CAGR of 8.8% from 2026 to 2032.

Fecal Calprotectin Assays are in vitro diagnostic reagents designed to qualitatively, semi-quantitatively or quantitatively detect calprotectin in human stool specimens as a non-invasive biomarker of intestinal inflammation. Commercial products are primarily based on enzyme linked immunosorbent assay, immunoturbidimetric assay, chemiluminescent immunoassay, fluorescence immunoassay and lateral flow immunochromatographic technologies, with quantitative laboratory assays representing an important form of routine clinical testing. Product configurations range from microplate reagent kits and analyzer-specific reagent packs to rapid test cassettes and fluorescence-based point-of-care formats, and commonly incorporate dedicated calibrators, controls and stool extraction systems. Fecal Calprotectin Assays are principally used in the initial evaluation of suspected inflammatory bowel disease, differentiation of inflammatory bowel disease from functional gastrointestinal disorders such as irritable bowel syndrome, and ongoing management of established Crohn’s disease and ulcerative colitis, including disease activity assessment, treatment-response monitoring and relapse-risk evaluation. The market therefore combines centralized laboratory immunodiagnostics with increasingly automated and rapid-testing workflows across gastroenterology and clinical laboratory settings.

Key Findings

Quantitative assays represent the principal commercial format across centralized laboratory and automated testing workflows

Europe has the highest concentration of established fecal calprotectin assay manufacturers and specialist diagnostic suppliers

The competitive structure combines multinational IVD groups with specialist gastrointestinal diagnostics companies and regional POCT manufacturers

Market Trends

The Fecal Calprotectin Assays market is shifting from conventional manual ELISA workflows toward faster and more automated testing formats. Immunoturbidimetric assays are increasingly integrated into routine clinical chemistry analyzers, while chemiluminescent and fluorescence immunoassays enable higher-throughput or shorter-turnaround testing. At the same time, lateral flow products are evolving from visually interpreted qualitative tests toward reader-assisted quantitative and semi-quantitative formats. Product development is increasingly focused on broader analytical ranges, improved stool extraction consistency, reduced hands-on time and compatibility with existing laboratory platforms. These changes are gradually positioning fecal calprotectin as a more standardized routine biomarker rather than a specialist test limited to dedicated gastroenterology laboratories.

Market Dynamics

Drivers

Growth is supported by the expanding clinical use of non-invasive intestinal inflammation biomarkers in inflammatory bowel disease pathways. Fecal calprotectin testing can reduce unnecessary invasive diagnostic procedures in selected patients, support differentiation between inflammatory and functional gastrointestinal disorders, and provide repeatable monitoring for established Crohn’s disease and ulcerative colitis. Increasing adoption of treat-to-target disease management, greater use of biologic therapies and the need for objective follow-up biomarkers further support recurrent testing demand. Automation on mainstream chemistry and immunoassay platforms is also lowering workflow barriers for general clinical laboratories.

Restraints

Market expansion is constrained by variability in assay-specific reference ranges, cut-off interpretation and pre-analytical stool handling. Different extraction devices, analytical platforms and calibration systems may generate results that are not fully interchangeable, limiting standardization across institutions. In addition, fecal calprotectin is a marker of intestinal inflammation rather than a disease-specific biomarker, so elevated values may require additional clinical assessment. Price pressure from high-volume laboratory tenders and lower-cost rapid-test manufacturers can also compress reagent ASPs, particularly in mature and emerging markets with increasing supplier competition.

Opportunities

The strongest opportunities lie in wider integration of fecal calprotectin into routine IBD monitoring pathways and expansion beyond specialist gastroenterology centers. Automated immunoturbidimetric and chemiluminescent products can penetrate medium- and high-throughput laboratories that already operate compatible analyzers, while fluorescence and reader-based rapid tests can extend access to outpatient and decentralized settings. Emerging markets also offer room for increased penetration as awareness of IBD rises and laboratories shift from outsourced testing toward local testing. Further opportunities exist in digital patient monitoring, where home sample collection or near-patient testing may be linked with longitudinal disease-management programs.

Challenges

Long-term challenges include achieving stronger harmonization between assay systems, improving consistency of stool extraction and maintaining clinically meaningful cut-offs across different patient populations. Manufacturers also face the need to balance analytical performance with lower testing costs as laboratories consolidate purchasing volumes. Competition is intensifying as established gastrointestinal diagnostics specialists, multinational IVD companies and Asian POCT manufacturers increasingly address the same clinical workflow. Maintaining differentiation therefore depends on platform compatibility, automation, analytical range, turnaround time, clinical evidence and the ability to secure long-term laboratory adoption.

Industry Chain Analysis

The upstream segment of the Fecal Calprotectin Assays industry mainly comprises monoclonal and polyclonal antibody suppliers, recombinant antigen and calibrator producers, immunoassay membranes, latex particles, enzymes, chemiluminescent substrates, fluorescence labels, buffers, plastics and stool extraction components. These materials are converted by IVD manufacturers into ELISA kits, immunoturbidimetric reagents, analyzer-specific chemiluminescent packs, fluorescence test devices and lateral flow cassettes. Product value is created through antibody performance, assay calibration, analytical validation, manufacturing consistency, regulatory registration and platform integration rather than through raw material cost alone.

The downstream segment consists primarily of hospital laboratories, independent clinical laboratories, gastroenterology centers and selected decentralized testing settings. Automated products generate value through laboratory throughput and reduced manual handling, while rapid formats compete through turnaround time and accessibility. Reagents are recurring consumables, so installed analyzer access, distributor coverage, clinician familiarity and repeat-testing frequency are important determinants of lifetime customer value. Stool extraction systems and dedicated consumables can strengthen supplier lock-in but remain secondary to the core assay reagent economics.

Segment Insights

By assay principle, the market is structurally divided among enzyme linked immunosorbent assays, immunoturbidimetric assays, chemiluminescent immunoassays, fluorescence immunoassays and lateral flow immunochromatographic assays. ELISA remains an established reference format with broad manufacturer participation, while immunoturbidimetric testing has gained importance because it can be integrated into routine chemistry workflows and processed at higher throughput. Chemiluminescent assays strengthen automation within immunodiagnostic laboratories, whereas fluorescence and lateral flow formats address rapid and decentralized testing needs.

By result format, quantitative assays form the core of clinical disease management because serial numerical values support assessment of inflammatory activity and response to therapy. Semi-quantitative and qualitative products remain relevant in rapid screening and lower-complexity testing environments, particularly where analyzer infrastructure is limited. The market is therefore moving toward higher automation and quantitative output while maintaining a distinct role for simpler rapid-testing formats.

Downstream Market Opportunities

The largest long-term clinical opportunity remains management of established inflammatory bowel disease, where repeated testing can support disease activity assessment, treatment-response monitoring and relapse-risk evaluation without repeated invasive procedures. Initial evaluation of patients with persistent gastrointestinal symptoms is another important demand source, particularly when clinicians need to distinguish probable inflammatory disease from functional disorders before referring patients for endoscopy. Wider adoption in outpatient gastroenterology, community laboratories and decentralized testing could increase testing frequency while shortening the interval between clinical symptoms and objective inflammatory assessment.

Regional Insights

Europe represents the most developed supplier cluster for Fecal Calprotectin Assays, with a dense concentration of specialist gastrointestinal diagnostics companies in Switzerland, Germany, Italy, Spain, Norway, Belgium, France and other European markets. The region benefits from established IBD management pathways, broad laboratory familiarity with fecal calprotectin and a diverse mix of ELISA, immunoturbidimetric, chemiluminescent and rapid-testing suppliers. North America is characterized by strong participation from multinational IVD groups and established specialist suppliers, with automation and regulatory clearance remaining important competitive factors.

Asia-Pacific is developing through a combination of established Japanese and Korean manufacturers and a growing Chinese POCT and immunodiagnostics manufacturing base. Japan has differentiated automated fecal-testing platforms, while China has expanded rapidly across fluorescence immunoassay, lateral flow, immunoturbidimetric and chemiluminescent formats. India has a smaller but identifiable domestic manufacturing base. Southeast Asia and Taiwan remain more dependent on imported products and regional distribution networks, creating opportunities for both international manufacturers and cost-competitive Asian suppliers.

Competitive Landscape Analysis

The competitive landscape is moderately fragmented and includes both multinational IVD groups and highly specialized gastrointestinal diagnostics manufacturers. B?HLMANN Laboratories is a major specialist participant with ELISA, immunoturbidimetric and rapid quantitative solutions, while DiaSorin, Phadia under Thermo Fisher Scientific, Inova Diagnostics under Werfen, EIKEN CHEMICAL and Revvity-related businesses compete through automated immunodiagnostic or fecal-testing platforms. Specialist manufacturers including R-Biopharm, EUROSPITAL, Sentinel CH, Calpro, ALPCO, ORGENTEC, BioSystems and Immundiagnostik maintain strong positions in defined assay technologies or regional laboratory channels. Asian manufacturers including Boditech Med, Getein Biotech, Hangzhou AllTest, Xiamen Wiz Biotech, Sichuan Orienter and Agappe Diagnostics broaden competition in fluorescence immunoassay, rapid testing and cost-sensitive markets. Competitive differentiation increasingly depends on assay standardization, analytical range, compatibility with installed analyzers, stool extraction workflow, regulatory coverage and the ability to support recurrent testing programs rather than on reagent price alone.

Report Scope

LP Information, Inc. (LPI) ' newest research report, the “Fecal Calprotectin Assays Industry Forecast” looks at past sales and reviews total world Fecal Calprotectin Assays sales in 2025, providing a comprehensive analysis by region and market sector of projected Fecal Calprotectin Assays sales for 2026 through 2032. With Fecal Calprotectin Assays sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Fecal Calprotectin Assays industry.

This Insight Report provides a comprehensive analysis of the global Fecal Calprotectin Assays landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Fecal Calprotectin Assays portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Fecal Calprotectin Assays market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Fecal Calprotectin Assays and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Fecal Calprotectin Assays.

This report presents a comprehensive overview, market shares, and growth opportunities of Fecal Calprotectin Assays market by product type, application, key manufacturers and key regions and countries.

Market Segmentation

Segmentation by Type:

• Enzyme Linked Immunosorbent Assay
• Immunoturbidimetric Assay
• Chemiluminescent Immunoassay
• Fluorescence Immunoassay
• Lateral Flow Immunochromatographic Assay
• Other

Segmentation by Result Format:

• Quantitative
• Semi Quantitative
• Qualitative
• Other

Segmentation by Application:

• Initial IBD Evaluation and Differential Diagnosis
• Established IBD Disease Management
• Other

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• B?HLMANN Laboratories AG
• DiaSorin S.p.A.
• Phadia AB
• Inova Diagnostics, Inc.
• EIKEN CHEMICAL CO., LTD.
• Revvity, Inc.
• R-Biopharm AG
• EUROSPITAL S.p.A.
• SENTINEL CH. SpA
• Calpro AS
• ALPCO
• ORGENTEC Diagnostika GmbH
• BioSystems S.A.
• Boditech Med Inc.
• Getein Biotech, Inc.
• Hangzhou AllTest Biotech Co., Ltd.
• Xiamen Wiz Biotech Co., Ltd.
• Sichuan Orienter Bioengineering Co., Ltd.
• Agappe Diagnostics Ltd.
• Immundiagnostik AG
• Alfresa Pharma Corporation
• DiaSource ImmunoAssays S.A.
• Epitope Diagnostics, Inc.
• ScheBo Biotech AG
• Vitassay Healthcare, S.L.U.
• Certest Biotec S.L.
• VEDA.LAB
• Shijiazhuang Hipro Biotechnology Co., Ltd.
• Guangzhou Forreal Biotechnology Co., Ltd.
• AccuBioTech Co., Ltd.
• Zhejiang Wantaifu Biotechnology Co., Ltd.
• Famid Biomedical Technology Tianjin Co., Ltd.

Key Questions Addressed in this Report

• What is the 10-year outlook for the global Fecal Calprotectin Assays market?
• What factors are driving Fecal Calprotectin Assays market growth, globally and by region?
• Which technologies are poised for the fastest growth by market and region?
• How do Fecal Calprotectin Assays market opportunities vary by end market size?
• How does Fecal Calprotectin Assays break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Fecal Calprotectin Assays Annual Sales 2021-2032
  2.1.2 World Current & Future Analysis for Fecal Calprotectin Assays by Geographic Region, 2021, 2025 & 2032
  2.1.3 World Current & Future Analysis for Fecal Calprotectin Assays by Country/Region, 2021, 2025 & 2032
2.2 Fecal Calprotectin Assays Segment by Type
  2.2.1 Enzyme Linked Immunosorbent Assay
  2.2.2 Immunoturbidimetric Assay
  2.2.3 Chemiluminescent Immunoassay
  2.2.4 Fluorescence Immunoassay
  2.2.5 Lateral Flow Immunochromatographic Assay
  2.2.6 Other
  2.2.7 Fecal Calprotectin Assays Sales by Type
    2.2.7.1 Global Fecal Calprotectin Assays Sales Market Share by Type (2021-2026)
    2.2.7.2 Global Fecal Calprotectin Assays Revenue and Market Share by Type (2021-2026)
    2.2.7.3 Global Fecal Calprotectin Assays Sale Price by Type (2021-2026)
2.3 Fecal Calprotectin Assays Segment by Result Format
  2.3.1 Quantitative
  2.3.2 Semi Quantitative
  2.3.3 Qualitative
  2.3.4 Other
  2.3.5 Fecal Calprotectin Assays Sales by Result Format
    2.3.5.1 Global Fecal Calprotectin Assays Sales Market Share by Result Format (2021-2026)
    2.3.5.2 Global Fecal Calprotectin Assays Revenue and Market Share by Result Format (2021-2026)
    2.3.5.3 Global Fecal Calprotectin Assays Sale Price by Result Format (2021-2026)
2.4 Fecal Calprotectin Assays Segment by Application
  2.4.1 Initial IBD Evaluation and Differential Diagnosis
  2.4.2 Established IBD Disease Management
  2.4.3 Other
  2.4.4 Fecal Calprotectin Assays Sales by Application
    2.4.4.1 Global Fecal Calprotectin Assays Sale Market Share by Application (2021-2026)
    2.4.4.2 Global Fecal Calprotectin Assays Revenue and Market Share by Application (2021-2026)
    2.4.4.3 Global Fecal Calprotectin Assays Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Fecal Calprotectin Assays Breakdown Data by Company
  3.1.1 Global Fecal Calprotectin Assays Annual Sales by Company (2021-2026)
  3.1.2 Global Fecal Calprotectin Assays Sales Market Share by Company (2021-2026)
3.2 Global Fecal Calprotectin Assays Annual Revenue by Company (2021-2026)
  3.2.1 Global Fecal Calprotectin Assays Revenue by Company (2021-2026)
  3.2.2 Global Fecal Calprotectin Assays Revenue Market Share by Company (2021-2026)
3.3 Global Fecal Calprotectin Assays Sale Price by Company
3.4 Key Manufacturers Fecal Calprotectin Assays Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Fecal Calprotectin Assays Product Location Distribution
  3.4.2 Players Fecal Calprotectin Assays Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR FECAL CALPROTECTIN ASSAYS BY GEOGRAPHIC REGION

4.1 World Historic Fecal Calprotectin Assays Market Size by Geographic Region (2021-2026)
  4.1.1 Global Fecal Calprotectin Assays Annual Sales by Geographic Region (2021-2026)
  4.1.2 Global Fecal Calprotectin Assays Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Fecal Calprotectin Assays Market Size by Country/Region (2021-2026)
  4.2.1 Global Fecal Calprotectin Assays Annual Sales by Country/Region (2021-2026)
  4.2.2 Global Fecal Calprotectin Assays Annual Revenue by Country/Region (2021-2026)
4.3 Americas Fecal Calprotectin Assays Sales Growth
4.4 APAC Fecal Calprotectin Assays Sales Growth
4.5 Europe Fecal Calprotectin Assays Sales Growth
4.6 Middle East & Africa Fecal Calprotectin Assays Sales Growth

5 AMERICAS

5.1 Americas Fecal Calprotectin Assays Sales by Country
  5.1.1 Americas Fecal Calprotectin Assays Sales by Country (2021-2026)
  5.1.2 Americas Fecal Calprotectin Assays Revenue by Country (2021-2026)
5.2 Americas Fecal Calprotectin Assays Sales by Type (2021-2026)
5.3 Americas Fecal Calprotectin Assays Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Fecal Calprotectin Assays Sales by Region
  6.1.1 APAC Fecal Calprotectin Assays Sales by Region (2021-2026)
  6.1.2 APAC Fecal Calprotectin Assays Revenue by Region (2021-2026)
6.2 APAC Fecal Calprotectin Assays Sales by Type (2021-2026)
6.3 APAC Fecal Calprotectin Assays Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Fecal Calprotectin Assays by Country
  7.1.1 Europe Fecal Calprotectin Assays Sales by Country (2021-2026)
  7.1.2 Europe Fecal Calprotectin Assays Revenue by Country (2021-2026)
7.2 Europe Fecal Calprotectin Assays Sales by Type (2021-2026)
7.3 Europe Fecal Calprotectin Assays Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Fecal Calprotectin Assays by Country
  8.1.1 Middle East & Africa Fecal Calprotectin Assays Sales by Country (2021-2026)
  8.1.2 Middle East & Africa Fecal Calprotectin Assays Revenue by Country (2021-2026)
8.2 Middle East & Africa Fecal Calprotectin Assays Sales by Type (2021-2026)
8.3 Middle East & Africa Fecal Calprotectin Assays Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Fecal Calprotectin Assays
10.3 Manufacturing Process Analysis of Fecal Calprotectin Assays
10.4 Industry Chain Structure of Fecal Calprotectin Assays

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Fecal Calprotectin Assays Distributors
11.3 Fecal Calprotectin Assays Customer

12 WORLD FORECAST REVIEW FOR FECAL CALPROTECTIN ASSAYS BY GEOGRAPHIC REGION

12.1 Global Fecal Calprotectin Assays Market Size Forecast by Region
  12.1.1 Global Fecal Calprotectin Assays Forecast by Region (2027-2032)
  12.1.2 Global Fecal Calprotectin Assays Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Fecal Calprotectin Assays Forecast by Type (2027-2032)
12.7 Global Fecal Calprotectin Assays Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 B?HLMANN Laboratories AG
  13.1.1 B?HLMANN Laboratories AG Company Information
  13.1.2 B?HLMANN Laboratories AG Fecal Calprotectin Assays Product Portfolios and Specifications
  13.1.3 B?HLMANN Laboratories AG Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.1.4 B?HLMANN Laboratories AG Main Business Overview
  13.1.5 B?HLMANN Laboratories AG Latest Developments
13.2 DiaSorin S.p.A.
  13.2.1 DiaSorin S.p.A. Company Information
  13.2.2 DiaSorin S.p.A. Fecal Calprotectin Assays Product Portfolios and Specifications
  13.2.3 DiaSorin S.p.A. Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.2.4 DiaSorin S.p.A. Main Business Overview
  13.2.5 DiaSorin S.p.A. Latest Developments
13.3 Phadia AB
  13.3.1 Phadia AB Company Information
  13.3.2 Phadia AB Fecal Calprotectin Assays Product Portfolios and Specifications
  13.3.3 Phadia AB Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.3.4 Phadia AB Main Business Overview
  13.3.5 Phadia AB Latest Developments
13.4 Inova Diagnostics, Inc.
  13.4.1 Inova Diagnostics, Inc. Company Information
  13.4.2 Inova Diagnostics, Inc. Fecal Calprotectin Assays Product Portfolios and Specifications
  13.4.3 Inova Diagnostics, Inc. Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.4.4 Inova Diagnostics, Inc. Main Business Overview
  13.4.5 Inova Diagnostics, Inc. Latest Developments
13.5 EIKEN CHEMICAL CO., LTD.
  13.5.1 EIKEN CHEMICAL CO., LTD. Company Information
  13.5.2 EIKEN CHEMICAL CO., LTD. Fecal Calprotectin Assays Product Portfolios and Specifications
  13.5.3 EIKEN CHEMICAL CO., LTD. Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.5.4 EIKEN CHEMICAL CO., LTD. Main Business Overview
  13.5.5 EIKEN CHEMICAL CO., LTD. Latest Developments
13.6 Revvity, Inc.
  13.6.1 Revvity, Inc. Company Information
  13.6.2 Revvity, Inc. Fecal Calprotectin Assays Product Portfolios and Specifications
  13.6.3 Revvity, Inc. Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.6.4 Revvity, Inc. Main Business Overview
  13.6.5 Revvity, Inc. Latest Developments
13.7 R-Biopharm AG
  13.7.1 R-Biopharm AG Company Information
  13.7.2 R-Biopharm AG Fecal Calprotectin Assays Product Portfolios and Specifications
  13.7.3 R-Biopharm AG Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.7.4 R-Biopharm AG Main Business Overview
  13.7.5 R-Biopharm AG Latest Developments
13.8 EUROSPITAL S.p.A.
  13.8.1 EUROSPITAL S.p.A. Company Information
  13.8.2 EUROSPITAL S.p.A. Fecal Calprotectin Assays Product Portfolios and Specifications
  13.8.3 EUROSPITAL S.p.A. Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.8.4 EUROSPITAL S.p.A. Main Business Overview
  13.8.5 EUROSPITAL S.p.A. Latest Developments
13.9 SENTINEL CH. SpA
  13.9.1 SENTINEL CH. SpA Company Information
  13.9.2 SENTINEL CH. SpA Fecal Calprotectin Assays Product Portfolios and Specifications
  13.9.3 SENTINEL CH. SpA Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.9.4 SENTINEL CH. SpA Main Business Overview
  13.9.5 SENTINEL CH. SpA Latest Developments
13.10 Calpro AS
  13.10.1 Calpro AS Company Information
  13.10.2 Calpro AS Fecal Calprotectin Assays Product Portfolios and Specifications
  13.10.3 Calpro AS Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.10.4 Calpro AS Main Business Overview
  13.10.5 Calpro AS Latest Developments
13.11 ALPCO
  13.11.1 ALPCO Company Information
  13.11.2 ALPCO Fecal Calprotectin Assays Product Portfolios and Specifications
  13.11.3 ALPCO Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.11.4 ALPCO Main Business Overview
  13.11.5 ALPCO Latest Developments
13.12 ORGENTEC Diagnostika GmbH
  13.12.1 ORGENTEC Diagnostika GmbH Company Information
  13.12.2 ORGENTEC Diagnostika GmbH Fecal Calprotectin Assays Product Portfolios and Specifications
  13.12.3 ORGENTEC Diagnostika GmbH Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.12.4 ORGENTEC Diagnostika GmbH Main Business Overview
  13.12.5 ORGENTEC Diagnostika GmbH Latest Developments
13.13 BioSystems S.A.
  13.13.1 BioSystems S.A. Company Information
  13.13.2 BioSystems S.A. Fecal Calprotectin Assays Product Portfolios and Specifications
  13.13.3 BioSystems S.A. Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.13.4 BioSystems S.A. Main Business Overview
  13.13.5 BioSystems S.A. Latest Developments
13.14 Boditech Med Inc.
  13.14.1 Boditech Med Inc. Company Information
  13.14.2 Boditech Med Inc. Fecal Calprotectin Assays Product Portfolios and Specifications
  13.14.3 Boditech Med Inc. Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.14.4 Boditech Med Inc. Main Business Overview
  13.14.5 Boditech Med Inc. Latest Developments
13.15 Getein Biotech, Inc.
  13.15.1 Getein Biotech, Inc. Company Information
  13.15.2 Getein Biotech, Inc. Fecal Calprotectin Assays Product Portfolios and Specifications
  13.15.3 Getein Biotech, Inc. Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.15.4 Getein Biotech, Inc. Main Business Overview
  13.15.5 Getein Biotech, Inc. Latest Developments
13.16 Hangzhou AllTest Biotech Co., Ltd.
  13.16.1 Hangzhou AllTest Biotech Co., Ltd. Company Information
  13.16.2 Hangzhou AllTest Biotech Co., Ltd. Fecal Calprotectin Assays Product Portfolios and Specifications
  13.16.3 Hangzhou AllTest Biotech Co., Ltd. Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.16.4 Hangzhou AllTest Biotech Co., Ltd. Main Business Overview
  13.16.5 Hangzhou AllTest Biotech Co., Ltd. Latest Developments
13.17 Xiamen Wiz Biotech Co., Ltd.
  13.17.1 Xiamen Wiz Biotech Co., Ltd. Company Information
  13.17.2 Xiamen Wiz Biotech Co., Ltd. Fecal Calprotectin Assays Product Portfolios and Specifications
  13.17.3 Xiamen Wiz Biotech Co., Ltd. Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.17.4 Xiamen Wiz Biotech Co., Ltd. Main Business Overview
  13.17.5 Xiamen Wiz Biotech Co., Ltd. Latest Developments
13.18 Sichuan Orienter Bioengineering Co., Ltd.
  13.18.1 Sichuan Orienter Bioengineering Co., Ltd. Company Information
  13.18.2 Sichuan Orienter Bioengineering Co., Ltd. Fecal Calprotectin Assays Product Portfolios and Specifications
  13.18.3 Sichuan Orienter Bioengineering Co., Ltd. Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.18.4 Sichuan Orienter Bioengineering Co., Ltd. Main Business Overview
  13.18.5 Sichuan Orienter Bioengineering Co., Ltd. Latest Developments
13.19 Agappe Diagnostics Ltd.
  13.19.1 Agappe Diagnostics Ltd. Company Information
  13.19.2 Agappe Diagnostics Ltd. Fecal Calprotectin Assays Product Portfolios and Specifications
  13.19.3 Agappe Diagnostics Ltd. Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.19.4 Agappe Diagnostics Ltd. Main Business Overview
  13.19.5 Agappe Diagnostics Ltd. Latest Developments
13.20 Immundiagnostik AG
  13.20.1 Immundiagnostik AG Company Information
  13.20.2 Immundiagnostik AG Fecal Calprotectin Assays Product Portfolios and Specifications
  13.20.3 Immundiagnostik AG Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.20.4 Immundiagnostik AG Main Business Overview
  13.20.5 Immundiagnostik AG Latest Developments
13.21 Alfresa Pharma Corporation
  13.21.1 Alfresa Pharma Corporation Company Information
  13.21.2 Alfresa Pharma Corporation Fecal Calprotectin Assays Product Portfolios and Specifications
  13.21.3 Alfresa Pharma Corporation Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.21.4 Alfresa Pharma Corporation Main Business Overview
  13.21.5 Alfresa Pharma Corporation Latest Developments
13.22 DiaSource ImmunoAssays S.A.
  13.22.1 DiaSource ImmunoAssays S.A. Company Information
  13.22.2 DiaSource ImmunoAssays S.A. Fecal Calprotectin Assays Product Portfolios and Specifications
  13.22.3 DiaSource ImmunoAssays S.A. Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.22.4 DiaSource ImmunoAssays S.A. Main Business Overview
  13.22.5 DiaSource ImmunoAssays S.A. Latest Developments
13.23 Epitope Diagnostics, Inc.
  13.23.1 Epitope Diagnostics, Inc. Company Information
  13.23.2 Epitope Diagnostics, Inc. Fecal Calprotectin Assays Product Portfolios and Specifications
  13.23.3 Epitope Diagnostics, Inc. Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.23.4 Epitope Diagnostics, Inc. Main Business Overview
  13.23.5 Epitope Diagnostics, Inc. Latest Developments
13.24 ScheBo Biotech AG
  13.24.1 ScheBo Biotech AG Company Information
  13.24.2 ScheBo Biotech AG Fecal Calprotectin Assays Product Portfolios and Specifications
  13.24.3 ScheBo Biotech AG Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.24.4 ScheBo Biotech AG Main Business Overview
  13.24.5 ScheBo Biotech AG Latest Developments
13.25 Vitassay Healthcare, S.L.U.
  13.25.1 Vitassay Healthcare, S.L.U. Company Information
  13.25.2 Vitassay Healthcare, S.L.U. Fecal Calprotectin Assays Product Portfolios and Specifications
  13.25.3 Vitassay Healthcare, S.L.U. Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.25.4 Vitassay Healthcare, S.L.U. Main Business Overview
  13.25.5 Vitassay Healthcare, S.L.U. Latest Developments
13.26 Certest Biotec S.L.
  13.26.1 Certest Biotec S.L. Company Information
  13.26.2 Certest Biotec S.L. Fecal Calprotectin Assays Product Portfolios and Specifications
  13.26.3 Certest Biotec S.L. Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.26.4 Certest Biotec S.L. Main Business Overview
  13.26.5 Certest Biotec S.L. Latest Developments
13.27 VEDA.LAB
  13.27.1 VEDA.LAB Company Information
  13.27.2 VEDA.LAB Fecal Calprotectin Assays Product Portfolios and Specifications
  13.27.3 VEDA.LAB Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.27.4 VEDA.LAB Main Business Overview
  13.27.5 VEDA.LAB Latest Developments
13.28 Shijiazhuang Hipro Biotechnology Co., Ltd.
  13.28.1 Shijiazhuang Hipro Biotechnology Co., Ltd. Company Information
  13.28.2 Shijiazhuang Hipro Biotechnology Co., Ltd. Fecal Calprotectin Assays Product Portfolios and Specifications
  13.28.3 Shijiazhuang Hipro Biotechnology Co., Ltd. Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.28.4 Shijiazhuang Hipro Biotechnology Co., Ltd. Main Business Overview
  13.28.5 Shijiazhuang Hipro Biotechnology Co., Ltd. Latest Developments
13.29 Guangzhou Forreal Biotechnology Co., Ltd.
  13.29.1 Guangzhou Forreal Biotechnology Co., Ltd. Company Information
  13.29.2 Guangzhou Forreal Biotechnology Co., Ltd. Fecal Calprotectin Assays Product Portfolios and Specifications
  13.29.3 Guangzhou Forreal Biotechnology Co., Ltd. Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.29.4 Guangzhou Forreal Biotechnology Co., Ltd. Main Business Overview
  13.29.5 Guangzhou Forreal Biotechnology Co., Ltd. Latest Developments
13.30 AccuBioTech Co., Ltd.
  13.30.1 AccuBioTech Co., Ltd. Company Information
  13.30.2 AccuBioTech Co., Ltd. Fecal Calprotectin Assays Product Portfolios and Specifications
  13.30.3 AccuBioTech Co., Ltd. Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.30.4 AccuBioTech Co., Ltd. Main Business Overview
  13.30.5 AccuBioTech Co., Ltd. Latest Developments
13.31 Zhejiang Wantaifu Biotechnology Co., Ltd.
  13.31.1 Zhejiang Wantaifu Biotechnology Co., Ltd. Company Information
  13.31.2 Zhejiang Wantaifu Biotechnology Co., Ltd. Fecal Calprotectin Assays Product Portfolios and Specifications
  13.31.3 Zhejiang Wantaifu Biotechnology Co., Ltd. Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.31.4 Zhejiang Wantaifu Biotechnology Co., Ltd. Main Business Overview
  13.31.5 Zhejiang Wantaifu Biotechnology Co., Ltd. Latest Developments
13.32 Famid Biomedical Technology Tianjin Co., Ltd.
  13.32.1 Famid Biomedical Technology Tianjin Co., Ltd. Company Information
  13.32.2 Famid Biomedical Technology Tianjin Co., Ltd. Fecal Calprotectin Assays Product Portfolios and Specifications
  13.32.3 Famid Biomedical Technology Tianjin Co., Ltd. Fecal Calprotectin Assays Sales, Revenue, Price and Gross Margin (2021-2026)
  13.32.4 Famid Biomedical Technology Tianjin Co., Ltd. Main Business Overview
  13.32.5 Famid Biomedical Technology Tianjin Co., Ltd. Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Fecal Calprotectin Assays Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Fecal Calprotectin Assays Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Enzyme Linked Immunosorbent Assay
Table 4. Major Players of Immunoturbidimetric Assay
Table 5. Major Players of Chemiluminescent Immunoassay
Table 6. Major Players of Fluorescence Immunoassay
Table 7. Major Players of Lateral Flow Immunochromatographic Assay
Table 8. Major Players of Other
Table 9. Global Fecal Calprotectin Assays Sales by Type (2021-2026) & (K Units)
Table 10. Global Fecal Calprotectin Assays Sales Market Share by Type (2021-2026)
Table 11. Global Fecal Calprotectin Assays Revenue by Type (2021-2026) & ($ million)
Table 12. Global Fecal Calprotectin Assays Revenue Market Share by Type (2021-2026)
Table 13. Global Fecal Calprotectin Assays Sale Price by Type (2021-2026) & (US$/Unit)
Table 14. Major Players of Quantitative
Table 15. Major Players of Semi Quantitative
Table 16. Major Players of Qualitative
Table 17. Major Players of Other
Table 18. Global Fecal Calprotectin Assays Sales by Result Format (2021-2026) & (K Units)
Table 19. Global Fecal Calprotectin Assays Sales Market Share by Result Format (2021-2026)
Table 20. Global Fecal Calprotectin Assays Revenue by Result Format (2021-2026) & ($ million)
Table 21. Global Fecal Calprotectin Assays Revenue Market Share by Result Format (2021-2026)
Table 22. Global Fecal Calprotectin Assays Sale Price by Result Format (2021-2026) & (US$/Unit)
Table 23. Global Fecal Calprotectin Assays Sale by Application (2021-2026) & (K Units)
Table 24. Global Fecal Calprotectin Assays Sale Market Share by Application (2021-2026)
Table 25. Global Fecal Calprotectin Assays Revenue by Application (2021-2026) & ($ million)
Table 26. Global Fecal Calprotectin Assays Revenue Market Share by Application (2021-2026)
Table 27. Global Fecal Calprotectin Assays Sale Price by Application (2021-2026) & (US$/Unit)
Table 28. Global Fecal Calprotectin Assays Sales by Company (2021-2026) & (K Units)
Table 29. Global Fecal Calprotectin Assays Sales Market Share by Company (2021-2026)
Table 30. Global Fecal Calprotectin Assays Revenue by Company (2021-2026) & ($ millions)
Table 31. Global Fecal Calprotectin Assays Revenue Market Share by Company (2021-2026)
Table 32. Global Fecal Calprotectin Assays Sale Price by Company (2021-2026) & (US$/Unit)
Table 33. Key Manufacturers Fecal Calprotectin Assays Producing Area Distribution and Sales Area
Table 34. Players Fecal Calprotectin Assays Products Offered
Table 35. Fecal Calprotectin Assays Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 36. New Products and Potential Entrants
Table 37. Market M&A Activity & Strategy
Table 38. Global Fecal Calprotectin Assays Sales by Geographic Region (2021-2026) & (K Units)
Table 39. Global Fecal Calprotectin Assays Sales Market Share Geographic Region (2021-2026)
Table 40. Global Fecal Calprotectin Assays Revenue by Geographic Region (2021-2026) & ($ millions)
Table 41. Global Fecal Calprotectin Assays Revenue Market Share by Geographic Region (2021-2026)
Table 42. Global Fecal Calprotectin Assays Sales by Country/Region (2021-2026) & (K Units)
Table 43. Global Fecal Calprotectin Assays Sales Market Share by Country/Region (2021-2026)
Table 44. Global Fecal Calprotectin Assays Revenue by Country/Region (2021-2026) & ($ millions)
Table 45. Global Fecal Calprotectin Assays Revenue Market Share by Country/Region (2021-2026)
Table 46. Americas Fecal Calprotectin Assays Sales by Country (2021-2026) & (K Units)
Table 47. Americas Fecal Calprotectin Assays Sales Market Share by Country (2021-2026)
Table 48. Americas Fecal Calprotectin Assays Revenue by Country (2021-2026) & ($ millions)
Table 49. Americas Fecal Calprotectin Assays Sales by Type (2021-2026) & (K Units)
Table 50. Americas Fecal Calprotectin Assays Sales by Application (2021-2026) & (K Units)
Table 51. APAC Fecal Calprotectin Assays Sales by Region (2021-2026) & (K Units)
Table 52. APAC Fecal Calprotectin Assays Sales Market Share by Region (2021-2026)
Table 53. APAC Fecal Calprotectin Assays Revenue by Region (2021-2026) & ($ millions)
Table 54. APAC Fecal Calprotectin Assays Sales by Type (2021-2026) & (K Units)
Table 55. APAC Fecal Calprotectin Assays Sales by Application (2021-2026) & (K Units)
Table 56. Europe Fecal Calprotectin Assays Sales by Country (2021-2026) & (K Units)
Table 57. Europe Fecal Calprotectin Assays Revenue by Country (2021-2026) & ($ millions)
Table 58. Europe Fecal Calprotectin Assays Sales by Type (2021-2026) & (K Units)
Table 59. Europe Fecal Calprotectin Assays Sales by Application (2021-2026) & (K Units)
Table 60. Middle East & Africa Fecal Calprotectin Assays Sales by Country (2021-2026) & (K Units)
Table 61. Middle East & Africa Fecal Calprotectin Assays Revenue Market Share by Country (2021-2026)
Table 62. Middle East & Africa Fecal Calprotectin Assays Sales by Type (2021-2026) & (K Units)
Table 63. Middle East & Africa Fecal Calprotectin Assays Sales by Application (2021-2026) & (K Units)
Table 64. Key Market Drivers & Growth Opportunities of Fecal Calprotectin Assays
Table 65. Key Market Challenges & Risks of Fecal Calprotectin Assays
Table 66. Key Industry Trends of Fecal Calprotectin Assays
Table 67. Fecal Calprotectin Assays Raw Material
Table 68. Key Suppliers of Raw Materials
Table 69. Fecal Calprotectin Assays Distributors List
Table 70. Fecal Calprotectin Assays Customer List
Table 71. Global Fecal Calprotectin Assays Sales Forecast by Region (2027-2032) & (K Units)
Table 72. Global Fecal Calprotectin Assays Revenue Forecast by Region (2027-2032) & ($ millions)
Table 73. Americas Fecal Calprotectin Assays Sales Forecast by Country (2027-2032) & (K Units)
Table 74. Americas Fecal Calprotectin Assays Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 75. APAC Fecal Calprotectin Assays Sales Forecast by Region (2027-2032) & (K Units)
Table 76. APAC Fecal Calprotectin Assays Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 77. Europe Fecal Calprotectin Assays Sales Forecast by Country (2027-2032) & (K Units)
Table 78. Europe Fecal Calprotectin Assays Revenue Forecast by Country (2027-2032) & ($ millions)
Table 79. Middle East & Africa Fecal Calprotectin Assays Sales Forecast by Country (2027-2032) & (K Units)
Table 80. Middle East & Africa Fecal Calprotectin Assays Revenue Forecast by Country (2027-2032) & ($ millions)
Table 81. Global Fecal Calprotectin Assays Sales Forecast by Type (2027-2032) & (K Units)
Table 82. Global Fecal Calprotectin Assays Revenue Forecast by Type (2027-2032) & ($ millions)
Table 83. Global Fecal Calprotectin Assays Sales Forecast by Application (2027-2032) & (K Units)
Table 84. Global Fecal Calprotectin Assays Revenue Forecast by Application (2027-2032) & ($ millions)
Table 85. B?HLMANN Laboratories AG Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 86. B?HLMANN Laboratories AG Fecal Calprotectin Assays Product Portfolios and Specifications
Table 87. B?HLMANN Laboratories AG Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 88. B?HLMANN Laboratories AG Main Business
Table 89. B?HLMANN Laboratories AG Latest Developments
Table 90. DiaSorin S.p.A. Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 91. DiaSorin S.p.A. Fecal Calprotectin Assays Product Portfolios and Specifications
Table 92. DiaSorin S.p.A. Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 93. DiaSorin S.p.A. Main Business
Table 94. DiaSorin S.p.A. Latest Developments
Table 95. Phadia AB Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 96. Phadia AB Fecal Calprotectin Assays Product Portfolios and Specifications
Table 97. Phadia AB Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 98. Phadia AB Main Business
Table 99. Phadia AB Latest Developments
Table 100. Inova Diagnostics, Inc. Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 101. Inova Diagnostics, Inc. Fecal Calprotectin Assays Product Portfolios and Specifications
Table 102. Inova Diagnostics, Inc. Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 103. Inova Diagnostics, Inc. Main Business
Table 104. Inova Diagnostics, Inc. Latest Developments
Table 105. EIKEN CHEMICAL CO., LTD. Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 106. EIKEN CHEMICAL CO., LTD. Fecal Calprotectin Assays Product Portfolios and Specifications
Table 107. EIKEN CHEMICAL CO., LTD. Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 108. EIKEN CHEMICAL CO., LTD. Main Business
Table 109. EIKEN CHEMICAL CO., LTD. Latest Developments
Table 110. Revvity, Inc. Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 111. Revvity, Inc. Fecal Calprotectin Assays Product Portfolios and Specifications
Table 112. Revvity, Inc. Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 113. Revvity, Inc. Main Business
Table 114. Revvity, Inc. Latest Developments
Table 115. R-Biopharm AG Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 116. R-Biopharm AG Fecal Calprotectin Assays Product Portfolios and Specifications
Table 117. R-Biopharm AG Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 118. R-Biopharm AG Main Business
Table 119. R-Biopharm AG Latest Developments
Table 120. EUROSPITAL S.p.A. Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 121. EUROSPITAL S.p.A. Fecal Calprotectin Assays Product Portfolios and Specifications
Table 122. EUROSPITAL S.p.A. Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 123. EUROSPITAL S.p.A. Main Business
Table 124. EUROSPITAL S.p.A. Latest Developments
Table 125. SENTINEL CH. SpA Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 126. SENTINEL CH. SpA Fecal Calprotectin Assays Product Portfolios and Specifications
Table 127. SENTINEL CH. SpA Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 128. SENTINEL CH. SpA Main Business
Table 129. SENTINEL CH. SpA Latest Developments
Table 130. Calpro AS Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 131. Calpro AS Fecal Calprotectin Assays Product Portfolios and Specifications
Table 132. Calpro AS Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 133. Calpro AS Main Business
Table 134. Calpro AS Latest Developments
Table 135. ALPCO Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 136. ALPCO Fecal Calprotectin Assays Product Portfolios and Specifications
Table 137. ALPCO Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 138. ALPCO Main Business
Table 139. ALPCO Latest Developments
Table 140. ORGENTEC Diagnostika GmbH Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 141. ORGENTEC Diagnostika GmbH Fecal Calprotectin Assays Product Portfolios and Specifications
Table 142. ORGENTEC Diagnostika GmbH Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 143. ORGENTEC Diagnostika GmbH Main Business
Table 144. ORGENTEC Diagnostika GmbH Latest Developments
Table 145. BioSystems S.A. Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 146. BioSystems S.A. Fecal Calprotectin Assays Product Portfolios and Specifications
Table 147. BioSystems S.A. Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 148. BioSystems S.A. Main Business
Table 149. BioSystems S.A. Latest Developments
Table 150. Boditech Med Inc. Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 151. Boditech Med Inc. Fecal Calprotectin Assays Product Portfolios and Specifications
Table 152. Boditech Med Inc. Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 153. Boditech Med Inc. Main Business
Table 154. Boditech Med Inc. Latest Developments
Table 155. Getein Biotech, Inc. Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 156. Getein Biotech, Inc. Fecal Calprotectin Assays Product Portfolios and Specifications
Table 157. Getein Biotech, Inc. Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 158. Getein Biotech, Inc. Main Business
Table 159. Getein Biotech, Inc. Latest Developments
Table 160. Hangzhou AllTest Biotech Co., Ltd. Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 161. Hangzhou AllTest Biotech Co., Ltd. Fecal Calprotectin Assays Product Portfolios and Specifications
Table 162. Hangzhou AllTest Biotech Co., Ltd. Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 163. Hangzhou AllTest Biotech Co., Ltd. Main Business
Table 164. Hangzhou AllTest Biotech Co., Ltd. Latest Developments
Table 165. Xiamen Wiz Biotech Co., Ltd. Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 166. Xiamen Wiz Biotech Co., Ltd. Fecal Calprotectin Assays Product Portfolios and Specifications
Table 167. Xiamen Wiz Biotech Co., Ltd. Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 168. Xiamen Wiz Biotech Co., Ltd. Main Business
Table 169. Xiamen Wiz Biotech Co., Ltd. Latest Developments
Table 170. Sichuan Orienter Bioengineering Co., Ltd. Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 171. Sichuan Orienter Bioengineering Co., Ltd. Fecal Calprotectin Assays Product Portfolios and Specifications
Table 172. Sichuan Orienter Bioengineering Co., Ltd. Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 173. Sichuan Orienter Bioengineering Co., Ltd. Main Business
Table 174. Sichuan Orienter Bioengineering Co., Ltd. Latest Developments
Table 175. Agappe Diagnostics Ltd. Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 176. Agappe Diagnostics Ltd. Fecal Calprotectin Assays Product Portfolios and Specifications
Table 177. Agappe Diagnostics Ltd. Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 178. Agappe Diagnostics Ltd. Main Business
Table 179. Agappe Diagnostics Ltd. Latest Developments
Table 180. Immundiagnostik AG Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 181. Immundiagnostik AG Fecal Calprotectin Assays Product Portfolios and Specifications
Table 182. Immundiagnostik AG Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 183. Immundiagnostik AG Main Business
Table 184. Immundiagnostik AG Latest Developments
Table 185. Alfresa Pharma Corporation Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 186. Alfresa Pharma Corporation Fecal Calprotectin Assays Product Portfolios and Specifications
Table 187. Alfresa Pharma Corporation Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 188. Alfresa Pharma Corporation Main Business
Table 189. Alfresa Pharma Corporation Latest Developments
Table 190. DiaSource ImmunoAssays S.A. Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 191. DiaSource ImmunoAssays S.A. Fecal Calprotectin Assays Product Portfolios and Specifications
Table 192. DiaSource ImmunoAssays S.A. Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 193. DiaSource ImmunoAssays S.A. Main Business
Table 194. DiaSource ImmunoAssays S.A. Latest Developments
Table 195. Epitope Diagnostics, Inc. Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 196. Epitope Diagnostics, Inc. Fecal Calprotectin Assays Product Portfolios and Specifications
Table 197. Epitope Diagnostics, Inc. Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 198. Epitope Diagnostics, Inc. Main Business
Table 199. Epitope Diagnostics, Inc. Latest Developments
Table 200. ScheBo Biotech AG Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 201. ScheBo Biotech AG Fecal Calprotectin Assays Product Portfolios and Specifications
Table 202. ScheBo Biotech AG Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 203. ScheBo Biotech AG Main Business
Table 204. ScheBo Biotech AG Latest Developments
Table 205. Vitassay Healthcare, S.L.U. Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 206. Vitassay Healthcare, S.L.U. Fecal Calprotectin Assays Product Portfolios and Specifications
Table 207. Vitassay Healthcare, S.L.U. Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 208. Vitassay Healthcare, S.L.U. Main Business
Table 209. Vitassay Healthcare, S.L.U. Latest Developments
Table 210. Certest Biotec S.L. Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 211. Certest Biotec S.L. Fecal Calprotectin Assays Product Portfolios and Specifications
Table 212. Certest Biotec S.L. Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 213. Certest Biotec S.L. Main Business
Table 214. Certest Biotec S.L. Latest Developments
Table 215. VEDA.LAB Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 216. VEDA.LAB Fecal Calprotectin Assays Product Portfolios and Specifications
Table 217. VEDA.LAB Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 218. VEDA.LAB Main Business
Table 219. VEDA.LAB Latest Developments
Table 220. Shijiazhuang Hipro Biotechnology Co., Ltd. Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 221. Shijiazhuang Hipro Biotechnology Co., Ltd. Fecal Calprotectin Assays Product Portfolios and Specifications
Table 222. Shijiazhuang Hipro Biotechnology Co., Ltd. Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 223. Shijiazhuang Hipro Biotechnology Co., Ltd. Main Business
Table 224. Shijiazhuang Hipro Biotechnology Co., Ltd. Latest Developments
Table 225. Guangzhou Forreal Biotechnology Co., Ltd. Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 226. Guangzhou Forreal Biotechnology Co., Ltd. Fecal Calprotectin Assays Product Portfolios and Specifications
Table 227. Guangzhou Forreal Biotechnology Co., Ltd. Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 228. Guangzhou Forreal Biotechnology Co., Ltd. Main Business
Table 229. Guangzhou Forreal Biotechnology Co., Ltd. Latest Developments
Table 230. AccuBioTech Co., Ltd. Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 231. AccuBioTech Co., Ltd. Fecal Calprotectin Assays Product Portfolios and Specifications
Table 232. AccuBioTech Co., Ltd. Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 233. AccuBioTech Co., Ltd. Main Business
Table 234. AccuBioTech Co., Ltd. Latest Developments
Table 235. Zhejiang Wantaifu Biotechnology Co., Ltd. Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 236. Zhejiang Wantaifu Biotechnology Co., Ltd. Fecal Calprotectin Assays Product Portfolios and Specifications
Table 237. Zhejiang Wantaifu Biotechnology Co., Ltd. Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 238. Zhejiang Wantaifu Biotechnology Co., Ltd. Main Business
Table 239. Zhejiang Wantaifu Biotechnology Co., Ltd. Latest Developments
Table 240. Famid Biomedical Technology Tianjin Co., Ltd. Basic Information, Fecal Calprotectin Assays Manufacturing Base, Sales Area and Its Competitors
Table 241. Famid Biomedical Technology Tianjin Co., Ltd. Fecal Calprotectin Assays Product Portfolios and Specifications
Table 242. Famid Biomedical Technology Tianjin Co., Ltd. Fecal Calprotectin Assays Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 243. Famid Biomedical Technology Tianjin Co., Ltd. Main Business
Table 244. Famid Biomedical Technology Tianjin Co., Ltd. Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Fecal Calprotectin Assays
Figure 2. Fecal Calprotectin Assays Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Fecal Calprotectin Assays Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Fecal Calprotectin Assays Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Fecal Calprotectin Assays Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Fecal Calprotectin Assays Sales Market Share by Country/Region (2025)
Figure 10. Fecal Calprotectin Assays Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Enzyme Linked Immunosorbent Assay
Figure 12. Product Picture of Immunoturbidimetric Assay
Figure 13. Product Picture of Chemiluminescent Immunoassay
Figure 14. Product Picture of Fluorescence Immunoassay
Figure 15. Product Picture of Lateral Flow Immunochromatographic Assay
Figure 16. Product Picture of Other
Figure 17. Global Fecal Calprotectin Assays Sales Market Share by Type in 2026
Figure 18. Global Fecal Calprotectin Assays Revenue Market Share by Type (2021-2026)
Figure 19. Product Picture of Quantitative
Figure 20. Product Picture of Semi Quantitative
Figure 21. Product Picture of Qualitative
Figure 22. Product Picture of Other
Figure 23. Global Fecal Calprotectin Assays Sales Market Share by Result Format in 2026
Figure 24. Global Fecal Calprotectin Assays Revenue Market Share by Result Format (2021-2026)
Figure 25. Fecal Calprotectin Assays Consumed in Initial IBD Evaluation and Differential Diagnosis
Figure 26. Global Fecal Calprotectin Assays Market: Initial IBD Evaluation and Differential Diagnosis (2021-2026) & (K Units)
Figure 27. Fecal Calprotectin Assays Consumed in Established IBD Disease Management
Figure 28. Global Fecal Calprotectin Assays Market: Established IBD Disease Management (2021-2026) & (K Units)
Figure 29. Fecal Calprotectin Assays Consumed in Other
Figure 30. Global Fecal Calprotectin Assays Market: Other (2021-2026) & (K Units)
Figure 31. Global Fecal Calprotectin Assays Sale Market Share by Application (2025)
Figure 32. Global Fecal Calprotectin Assays Revenue Market Share by Application in 2025
Figure 33. Fecal Calprotectin Assays Sales by Company in 2025 (K Units)
Figure 34. Global Fecal Calprotectin Assays Sales Market Share by Company in 2025
Figure 35. Fecal Calprotectin Assays Revenue by Company in 2025 ($ millions)
Figure 36. Global Fecal Calprotectin Assays Revenue Market Share by Company in 2025
Figure 37. Global Fecal Calprotectin Assays Sales Market Share by Geographic Region (2021-2026)
Figure 38. Global Fecal Calprotectin Assays Revenue Market Share by Geographic Region in 2025
Figure 39. Americas Fecal Calprotectin Assays Sales 2021-2026 (K Units)
Figure 40. Americas Fecal Calprotectin Assays Revenue 2021-2026 ($ millions)
Figure 41. APAC Fecal Calprotectin Assays Sales 2021-2026 (K Units)
Figure 42. APAC Fecal Calprotectin Assays Revenue 2021-2026 ($ millions)
Figure 43. Europe Fecal Calprotectin Assays Sales 2021-2026 (K Units)
Figure 44. Europe Fecal Calprotectin Assays Revenue 2021-2026 ($ millions)
Figure 45. Middle East & Africa Fecal Calprotectin Assays Sales 2021-2026 (K Units)
Figure 46. Middle East & Africa Fecal Calprotectin Assays Revenue 2021-2026 ($ millions)
Figure 47. Americas Fecal Calprotectin Assays Sales Market Share by Country in 2025
Figure 48. Americas Fecal Calprotectin Assays Revenue Market Share by Country (2021-2026)
Figure 49. Americas Fecal Calprotectin Assays Sales Market Share by Type (2021-2026)
Figure 50. Americas Fecal Calprotectin Assays Sales Market Share by Application (2021-2026)
Figure 51. United States Fecal Calprotectin Assays Revenue Growth 2021-2026 ($ millions)
Figure 52. Canada Fecal Calprotectin Assays Revenue Growth 2021-2026 ($ millions)
Figure 53. Mexico Fecal Calprotectin Assays Revenue Growth 2021-2026 ($ millions)
Figure 54. Brazil Fecal Calprotectin Assays Revenue Growth 2021-2026 ($ millions)
Figure 55. APAC Fecal Calprotectin Assays Sales Market Share by Region in 2025
Figure 56. APAC Fecal Calprotectin Assays Revenue Market Share by Region (2021-2026)
Figure 57. APAC Fecal Calprotectin Assays Sales Market Share by Type (2021-2026)
Figure 58. APAC Fecal Calprotectin Assays Sales Market Share by Application (2021-2026)
Figure 59. China Fecal Calprotectin Assays Revenue Growth 2021-2026 ($ millions)
Figure 60. Japan Fecal Calprotectin Assays Revenue Growth 2021-2026 ($ millions)
Figure 61. South Korea Fecal Calprotectin Assays Revenue Growth 2021-2026 ($ millions)
Figure 62. Southeast Asia Fecal Calprotectin Assays Revenue Growth 2021-2026 ($ millions)
Figure 63. India Fecal Calprotectin Assays Revenue Growth 2021-2026 ($ millions)
Figure 64. Australia Fecal Calprotectin Assays Revenue Growth 2021-2026 ($ millions)
Figure 65. China Taiwan Fecal Calprotectin Assays Revenue Growth 2021-2026 ($ millions)
Figure 66. Europe Fecal Calprotectin Assays Sales Market Share by Country in 2025
Figure 67. Europe Fecal Calprotectin Assays Revenue Market Share by Country (2021-2026)
Figure 68. Europe Fecal Calprotectin Assays Sales Market Share by Type (2021-2026)
Figure 69. Europe Fecal Calprotectin Assays Sales Market Share by Application (2021-2026)
Figure 70. Germany Fecal Calprotectin Assays Revenue Growth 2021-2026 ($ millions)
Figure 71. France Fecal Calprotectin Assays Revenue Growth 2021-2026 ($ millions)
Figure 72. UK Fecal Calprotectin Assays Revenue Growth 2021-2026 ($ millions)
Figure 73. Italy Fecal Calprotectin Assays Revenue Growth 2021-2026 ($ millions)
Figure 74. Russia Fecal Calprotectin Assays Revenue Growth 2021-2026 ($ millions)
Figure 75. Middle East & Africa Fecal Calprotectin Assays Sales Market Share by Country (2021-2026)
Figure 76. Middle East & Africa Fecal Calprotectin Assays Sales Market Share by Type (2021-2026)
Figure 77. Middle East & Africa Fecal Calprotectin Assays Sales Market Share by Application (2021-2026)
Figure 78. Egypt Fecal Calprotectin Assays Revenue Growth 2021-2026 ($ millions)
Figure 79. South Africa Fecal Calprotectin Assays Revenue Growth 2021-2026 ($ millions)
Figure 80. Israel Fecal Calprotectin Assays Revenue Growth 2021-2026 ($ millions)
Figure 81. Turkey Fecal Calprotectin Assays Revenue Growth 2021-2026 ($ millions)
Figure 82. GCC Countries Fecal Calprotectin Assays Revenue Growth 2021-2026 ($ millions)
Figure 83. Manufacturing Cost Structure Analysis of Fecal Calprotectin Assays in 2026
Figure 84. Manufacturing Process Analysis of Fecal Calprotectin Assays
Figure 85. Industry Chain Structure of Fecal Calprotectin Assays
Figure 86. Channels of Distribution
Figure 87. Global Fecal Calprotectin Assays Sales Market Forecast by Region (2027-2032)
Figure 88. Global Fecal Calprotectin Assays Revenue Market Share Forecast by Region (2027-2032)
Figure 89. Global Fecal Calprotectin Assays Sales Market Share Forecast by Type (2027-2032)
Figure 90. Global Fecal Calprotectin Assays Revenue Market Share Forecast by Type (2027-2032)
Figure 91. Global Fecal Calprotectin Assays Sales Market Share Forecast by Application (2027-2032)
Figure 92. Global Fecal Calprotectin Assays Revenue Market Share Forecast by Application (2027-2032)